Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday

Enliven Therapeutics (NASDAQ:ELVN) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Enliven Therapeutics to post earnings of ($0.44) per share for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Stock Down 0.1%

Shares of ELVN opened at $41.58 on Wednesday. The company has a market capitalization of $2.53 billion, a P/E ratio of -22.35 and a beta of 0.32. The firm has a 50 day moving average of $36.54 and a 200 day moving average of $27.06. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $48.53.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. HC Wainwright raised their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Finally, Mizuho raised their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $43.40.

Insider Buying and Selling

In related news, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares in the company, valued at $1,508,580. This represents a 16.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 16,230 shares of company stock worth $473,201. 25.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Commodore Capital LP boosted its holdings in Enliven Therapeutics by 0.4% in the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after purchasing an additional 17,809 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 1.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock worth $63,355,000 after acquiring an additional 44,713 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Enliven Therapeutics by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after acquiring an additional 142,378 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Enliven Therapeutics by 9.1% during the 4th quarter. State Street Corp now owns 1,052,862 shares of the company’s stock worth $16,214,000 after acquiring an additional 87,725 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.